Abstract Library

#4654 Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4462 Clustering of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) using machine learning (ML) and comparison with tumour, node, metastasis (TNM) staging: A population-based study using surveillance, epidemiology, and end results (SEER)

Introduction: TNM 8 is the staging system for GEP-NEN, guiding prognosis and treatment. However, it does not include important prognostic factors such as age, sex, race, and morphology.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, White B, Chandrakumaran K, Ramage J,

Keywords: Clustering, Machine learning, GEP-NEN, TNM Staging, Survival Analysis, SEER,

#4434 Treatment approaches for gastroenteropancreatic neuroendocrine neoplasms: A twelve-year experience at a single centre in Colombia

Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) have multiple treatment options, but their availability varies by cost.

Conference:

Presenting Author: Molina-Pimienta L

Authors: Molina-Pimienta L, Cuellar A, Tapiero-Garcia M, Romero-Rojas A, Sanchez-Castillo J,

Keywords: neuroendocrine tumour, Kaplan-Meier analysis, treatment, Lutetium-177, surgery,